STOCK TITAN

Tela Bio, Inc. - TELA STOCK NEWS

Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.

TELA Bio, Inc. (TELA) provides investors and medical professionals with centralized access to official announcements and market-moving developments for this innovative MedTech company. Our news hub tracks the commercial-stage company's progress in soft tissue reconstruction, including product launches, clinical trial updates, and strategic partnerships.

Discover timely updates on TELA Bio's OviTex portfolio advancements, regulatory milestones, and financial performance. The resource aggregates press releases related to hernia repair innovations, abdominal wall reconstruction techniques, and plastic surgery solutions while maintaining strict editorial neutrality.

Key content categories include FDA clearances, surgeon collaboration initiatives, earnings reports, and leadership updates. Bookmark this page for unfiltered access to primary source materials that inform investment analysis and industry trend monitoring.

Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA) reported third-quarter 2020 revenues of $5.3 million, a 34% increase year-over-year. This growth was tempered by lower than expected procedural volumes due to COVID-19. Gross profit reached $3.3 million, representing a 62% margin, down from 66% the previous year. Operating expenses rose to $10.2 million, leading to a loss from operations of $6.9 million and a net loss of $7.7 million. The company has $81.5 million in cash. TELA did not provide 2020 financial guidance due to pandemic-related uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Summary

MALVERN, Pa., Nov. 10, 2020 – TELA Bio, a medical technology company, announced its participation in two investor conferences. Management will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 10:15 AM EST and the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 10:30 AM EST. Live audio webcasts will be available on the company’s website. TELA Bio focuses on developing innovative tissue reinforcement materials for soft tissue reconstruction, backed by extensive scientific research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
conferences
-
Rhea-AI Summary

TELA Bio, Inc. (Nasdaq: TELA), a medical technology firm, will report its 2020 third quarter financial results on November 11, 2020. The company focuses on developing innovative tissue reinforcement materials for soft tissue reconstruction. A conference call will take place at 4:30 p.m. ET on the same day for management to discuss financial results and provide corporate updates. TELA Bio's products aim to improve existing biologics, reducing long-term exposure to synthetic materials, supported by extensive pre-clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
Rhea-AI Summary

TELA Bio, Inc. announced positive findings from the BRAVO study presented at the Americas Hernia Society Annual Meeting. The data demonstrated a low incidence of surgical site infections and no hernia recurrences at 30 days post-operation using OviTex in ventral hernia repairs. The study involved 85 subjects, with 50% being obese and 16% having a history of surgical infections. Long-term results showed no hernia recurrences among the initial 20 subjects after two years. TELA's OviTex aims to address unmet needs in soft tissue reconstruction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
none
-
Rhea-AI Summary

TELA Bio reported a revenue of $3.5 million for Q2 2020, marking a 6% increase from Q2 2019. Despite this growth, procedural volume declines due to the COVID-19 pandemic impacted results. Gross profit rose to $2.1 million, representing 59% of revenue, up from 58% in the previous year. Operating expenses increased to $7.3 million, leading to a loss from operations of $5.2 million. The company completed a public offering, raising approximately $45 million. Due to COVID-19 uncertainty, TELA will not provide 2020 financial guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
-
Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA), a medical technology company specializing in tissue reinforcement materials, will participate in the Canaccord Genuity 40th Annual Growth Conference from August 11-13, 2020. Management is set to present on August 13 at 1:30 p.m. ET. The conference will be held virtually, and interested parties can access the live webcast through the company's website. TELA Bio focuses on addressing unmet needs in soft tissue reconstruction with innovative products backed by extensive research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
Rhea-AI Summary

TELA Bio, Inc. (NASDAQ: TELA) announced it will report its second quarter financial results for 2020 on August 12, 2020. A conference call and webcast led by management will follow at 4:30 p.m. ET to discuss these results and provide a corporate update. TELA Bio specializes in tissue reinforcement materials aimed at soft tissue reconstruction needs, emphasizing the advantages of its products over existing biologics and synthetic materials. The company’s offerings are backed by robust pre-clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
-
Rhea-AI Summary

Tela Bio, Inc. has successfully closed its public offering, issuing 3,000,000 shares at $16.00 each, translating to gross proceeds of $48 million before costs. The underwriters have a 30-day option to buy an additional 450,000 shares. Jefferies LLC and Piper Sandler & Co. led the offering management, with a registration statement filed with the SEC now effective. TELA specializes in innovative tissue reinforcement materials aimed at enhancing soft tissue reconstruction, with a focus on minimizing the limitations of existing products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
-
Rhea-AI Summary

TELA Bio, Inc. announced the pricing of its underwritten public offering of 3,000,000 shares at $16.00 per share, aiming for gross proceeds of $48 million. The offering includes a 30-day option for underwriters to purchase an additional 450,000 shares. This offering is expected to close on June 30, 2020, pending customary conditions. Jefferies LLC and Piper Sandler & Co. are the book-running managers. TELA focuses on innovative tissue reinforcement materials for soft tissue reconstruction. The registration statement has been effective since June 25, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.74%
Tags
Rhea-AI Summary

TELA Bio, Inc. (TELA) has announced a proposed underwritten public offering of 3,000,000 shares of its common stock, with an option for underwriters to purchase an additional 450,000 shares. The offering is subject to market conditions, and completion is uncertain. Jefferies LLC and Piper Sandler & Co. serve as joint book-running managers. A registration statement was filed with the SEC, but has not yet become effective, meaning sales cannot occur until it does. TELA aims to address unmet needs in soft tissue reconstruction with its innovative materials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.58%
Tags
Tela Bio, Inc.

Nasdaq:TELA

TELA Rankings

TELA Stock Data

37.82M
34.23M
8.45%
72.77%
1.19%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MALVERN